Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APC-100
- Development stage
- Preclinical
- Lead developer
- Progenicyte Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
**APC-100** is a preclinical oral small-molecule combination developed by Progenicyte Therapeutics. It combines KS217, which the company reports promotes proliferation of neural and mesenchymal stem cells, with phenserine, described as an amyloid precursor protein synthesis inhibitor. In 5xFAD transgenic Alzheimer's disease-model mice, the company reports increased neural stem-cell levels, enhanced neurogenesis, and improved cognitive function. The initial stated development focus is Acute Regression with Down Syndrome, with additional proposed applications in neurodegenerative, regenerative, ophthalmic, and cosmetic conditions. ([progenicytetherapeuticsinc.com](https://progenicytetherapeuticsinc.com/apc-100))
- Other names
- APC100APC-100APC 100KS217 + phenserine
02
Targets
eNSC (Endogenous neural stem cell)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on APC-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APC-100.